Background. It is unknown whether ribavirin (RBV) coadministration modifies the early rate of decline of hepatitis C virus (HCV) RNA in the liver versus plasma compartments, specifically.
The development of direct-acting antiviral agents (DAAs) for the treatment of hepatitis C virus (HCV) has resulted in high rates of sustained virologic response (SVR) in most patient populations [1] [2] [3] . Despite having a limited effect on plasma HCV RNA levels when given as monotherapy, ribavirin (RBV) was shown to accelerate the second-slope of viral decline when used in combination with interferon alpha [4] . RBV continues to contribute to the efficacy of DAA regimens by increasing overall SVR rates and allowing for shorter treatment durations, particularly in the most difficult-to-cure patients (eg, those with cirrhosis or prior treatment experience) [5] [6] [7] . In patients with HCV genotype (GT)1 infection, the multitargeted 3-DAA regimen of ombitasvir and paritaprevir codosed with ritonavir (OBV/PTV/r) and dasabuvir (DSV) has demonstrated consistently high rates of SVR [8] [9] [10] [11] [12] [13] [14] . In noncirrhotic patients with GT1a infection, the 3-DAA regimen alone demonstrated an SVR at 12 weeks post-treatment (SVR12) rate of 90% (185/205), whereas patients receiving the 3-DAA regimen with RBV had an SVR12 rate of 97% (97/100) [12] . Similarly, the addition of RBV to the 2-DAA regimen of OBV/PTV/r in patients with HCV GT4 infection resulted in an SVR of 100% (42/42), compared to 91% (40/44) without RBV [15] . However, knowledge of the direct impact of DAAs and RBV on liver HCV RNA kinetics and biology is limited.
Several mechanisms have been proposed to explain how RBV effects HCV treatment outcomes, including modulation of innate immune response [16] , inhibition of the NS5B HCV polymerase [17] , and mutagenesis leading to error catastrophe (ie, generation of nonviable viral quasispecies) [18] [19] [20] . However, none of these mechanisms has been demonstrated to be responsible for the observed effect of ribavirin on HCV. Prior work has demonstrated that in response to antiviral therapy, HCV RNA levels in the liver decrease more slowly than in plasma, but the cause for this is also unknown [21] .
Although a few studies have employed core needle biopsy (CNB) for liver sampling in HCV infection [22, 23] , the development and refinement of minimally invasive sampling techniques, such as liver fine needle aspiration (FNA), offer the ability to prospectively and serially sample the liver. This technique has been helpful in understanding liver viral kinetics, pharmacokinetics (PK), and pharmacodynamics (PD) in patients treated with a DAA in combination with pegylated interferon and RBV [21] . Early kinetic studies using interferon/RBV therapy demonstrated a biphasic decline in HCV RNA levels within the plasma, in which the first phase of decline represented blocking of viral particle production in hepatocytes and the second phase decline was due to the progressive cure of hepatocytes from HCV [24, 25] . The addition of an HCV NS3/4A protease inhibitor (PI) increased HCV RNA decline in both phases compared to interferon therapy alone [26] . However, it is unknown how the addition of RBV to an interferon-free DAA regimen differentially impinges upon HCV RNA levels in the liver and plasma compartments.
In the current study, we evaluated HCV RNA decline in both the plasma and liver tissue, as well as the PK of 3 DAAs, in patients with chronic HCV GT1a treated with OBV/ PTV/r plus DSV for 12 weeks with variable RBV dosing.
METHODS

Study Overview and Patient Population
This trial was a phase 2, partially randomized, open-label, exploratory study (NCT02493855) performed at 2 sites, and designed to evaluate the kinetics of viral load decline with OBV/PTV/r plus DSV therapy in combination with variable RBV dosing in patients with chronic HCV GT1 infection. Paritaprevir was identified by AbbVie and Enanta.
All patients provided written informed consent. The study was designed by the investigators and the sponsor (AbbVie) and conducted in accordance with Good Clinical Practice Guidelines, and the ethics set forth by the Declaration of Helsinki, with independent ethics committee or institutional review board approval at all study sites.
Patients were enrolled into 3 study arms with variable RBV dosing (A, B, and C), as illustrated in Supplementary  Figure 1 . All patients received OBV/PTV/r (25/150/100 mg once daily [QD]) plus DSV (250 mg twice daily [BID]) for 12 weeks. For the first 2 weeks, patients received no RBV (arm A), weight-based RBV (arm B; 1000 mg divided and dosed BID if body weight was below 75 kg, or 1200 mg divided and dosed BID if body weight was equal to or above 75 kg), or low-dose (LD) RBV (arm C; 600 mg QD). For the last 10 weeks, patients in arm A received weight-based RBV and patients in arms B and C continued to receive weight-based and LD RBV, respectively. Patients were first randomized 1:1 into arms A and B. Once these arms were fully enrolled, arm C began enrollment.
Eligible patients were HCV treatment-naive adults at least 18 years of age with chronic HCV GT1a infection (Versant® HCV Genotype Inno-LiPA Assay, version 2.0; Siemens Healthcare Diagnostics, Tarrytown, NY). Patient inclusion criteria for the study also included a liver biopsy within 24 months of (or during) screening, or a screening FibroTest score of ≤0.72 and aminotransferase to platelet ratio index (APRI) ≤ 2, or a FibroScan® result of <12.5 kPa, demonstrating the absence of cirrhosis.
Liver Tissue Fine Needle Aspiration
Fine needle aspiration (FNA) of liver tissue was performed in up to 10 patients per arm who enrolled in the United States prior to dosing at day 1 and 4-6 hours after study drug dosing at weeks 1, 2, and 4 (optional). Patients were offered conscious sedation with an intravenous combination of midazolam and fentanyl prior to the FNA procedure. Vital signs and responsiveness were measured throughout. Ultrasound was used to determine FNA puncture site location, direction, and depth. Lidocaine (2%) was administered subcutaneously and intramuscularly via the needle tract to anesthetize the liver capsule. A sterile 20-gauge spinal needle was secured to a 10-mL syringe, which was then secured to a sterile Belpro syringe holder. The needle was inserted through the cutaneous incision under ultrasound guidance with the patient's breath held in end expiration. Liver tissue was then aspirated as the needle was withdrawn; individual samples were obtained from slightly variable directions through the incision. A postprocedure ultrasound was performed to exclude bleeding or hematoma. Postprocedure monitoring included pain and vital sign assessment; acetaminophen and morphine were administered as necessary. Patients were released after at least 2 hours of monitoring to ensure stable condition.
Four FNA samples were taken at each procedure. Two separate samples for PK analysis were immediately flash frozen in liquid nitrogen and then stored at −80°C until analysis. One sample for HCV RNA analysis was mixed with 100 μL of phosphate buffered saline and then flash-frozen in liquid nitrogen.
Assessment of Safety and Efficacy
Study visits were conducted on days 1, 2, 3, 4, and 5, and at weeks 1, 2, 4, 8, and 12 of the treatment period, and at weeks 4, 12, and 24 during the post-treatment period.
Safety and Tolerability
Patients underwent adverse event monitoring, vital sign measurements, physical examinations, and laboratory assessments throughout the study to assess safety and tolerability.
Efficacy
Plasma HCV RNA was assessed on study day 1 immediately prior to the morning dose of study drugs, and at 2, 4, 6, 8, and 12 hours after dosing and at each study visit using the Abbott RealTime HCV assay, which has a lower limit of quantification of 12 IU/ mL. Intrahepatic HCV RNA (IU/mL) was assessed using the Abbott RealTime HCV assay from the FNA samples collected.
HCV RNA Assessments
In order to evaluate recovery of HCV RNA in plasma and FNA samples, negative human plasma and rat FNA samples were spiked with 1000 IU/mL 3rd WHO international standard prior to preanalytical processing. Each sample was pretreated with 60 μL of Proteinase K for 30 minutes at 55°C and subsequently brought up to 1.2 mL using bulk lysis buffer (Abbott Molecular, Des Plaines, IL). Nucleic acids were extracted using the total nucleic acid extraction protocol (m2000-RNADNA-Plasma-LL-1000-88-v052413; Abbott Diagnostics, Abbott Park, IL) and amplified using the RealTime HCV assay. All FNA samples were subjected to the same preanalytical and extraction methods. Residual nucleic acids from the sample extraction were stored at −80°C for gene expression analyses.
Gene Expression to Determine Total Cells Per FNA
Residual nucleic acids from the FNA extraction sample were used to determine the number of cells per FNA sample (primary human hepatocytes were used as calibration material). A standard curve was generated by plotting the number of cells compared to the respective cycle number at which glyceraldehyde 3-phosphate dehydrogenase (GAPDH) became detectable above background threshold. More details are available in the Supplementary Materials and Methods.
Pharmacokinetics
Plasma samples for pharmacokinetic analysis were collected on study day 1 immediately prior to the morning dose and at 2, 4, 6, 8, and 12 hours after dosing; and at each study visit irrespective of drug dosing time (sparse samples). Liver and plasma drug concentrations for 5 metabolites (OBV, PTV, ritonavir, DSV, and dasabuvir metabolite [DSV M1]) were measured as previously described [27, 28] . Noncompartmental analyses were used to determine day 1 maximum observed concentration (C max ) and time to C max (T max ). For the sparse samples, the plasma concentration data were binned into different time intervals based on time after the last dose at each visit. Based on the binned data at week 2 or later, plasma concentrations for the time intervals of >22 to 26 hours and >10 to 14 hours were considered as steadystate trough plasma concentration (C trough ) for QD and BID drugs, respectively. Intrahepatic concentrations of OBV, PTV, RTV, DSV, and DSV M1 metabolite were summarized.
Endpoints
The primary endpoint of the study was to evaluate the effect of RBV on second-phase plasma HCV RNA decline from baseline through treatment week 2 in each study arm. The study also had a number of exploratory objectives, including the kinetics of HCV RNA decline within the liver, liver-to-plasma concentration ratios of DAAs, and the sustained virologic response at post-treatment week 12 (SVR12) for each study arm. Additional details on study outcomes and relevant statistical methods are available in the Supplementary Information.
Statistical Methods
The slope of the second phase HCV RNA decline was estimated using equations first described by Neumann et al., and described in more detail in the Supplementary Information [24] . This slope was compared between each treatment arm using Wilcoxon's rank sum test, in order to determine the impact of RBV dosing on HCV RNA kinetics.
RESULTS
Baseline Patient Demographics
Fifty-one patients were screened between 23 June 2015 and 11 March 2016; 5 patients failed screening and 46 patients with chronic HCV GT1a infection were enrolled and received study drugs. Enrolled patients were all HCV treatment-naive without cirrhosis. Twenty-one patients were enrolled in arm A, 19 in arm B, and 6 in arm C; treatment details are shown in Supplementary Figure 1 . The majority of patients were male (59%), white race (74%), and former injection drug users (54%). Patients had a median baseline HCV RNA level of 5.8 log 10 IU/ mL, and 46% of patients had baseline viral load ≥800 000 IU/ mL. Detailed patient demographics are available in Table 1 .
Sustained Virologic Response
Overall, 41/46 (89%, 95% confidence interval [CI], 77%-95%) patients achieved SVR12 in the intent-to-treat (ITT) population. Of the 5 patients who did not achieve SVR12, one patient had virologic failure, a relapse at post-treatment week 12. This patient had a baseline viral load of 9.7 million (7.0 log 10 ) IU/mL, and received OBV/PTV/r plus DSV for 12 weeks with weightbased RBV for the last 10 weeks (arm A). Four patients did not achieve SVR12 for other reasons, including noncompliance, withdrawn consent, loss to follow-up, and study drug discontinuation due to an adverse event. Response rates by treatment arm are summarized in Supplementary Figure 2 .
Safety and Tolerability
Across all arms, 87% (40/46) of patients experienced at least one adverse event (AE), the majority of which were mild to moderate in severity. One patient in arm A experienced a serious AE of depression and relapse to benzodiazepine and cocaine use, deemed by the investigator as having a reasonable possibility of being related to study drugs. One patient had a grade 3 hemoglobin decline (<8 g/dL), and grade 3 elevations of alanine aminotransferase (ALT) and total bilirubin occurred in 1 (2%) and 2 (4%) patients, respectively; all of these abnormalities were observed in patients randomized to weight-based RBV for all 12 weeks (arm B). One additional patient with an asymptomatic grade 2 ALT elevation was in arm B, discontinued study drug on day 22, and ALT levels returned to normal by post-treatment day 44. Treatment-emergent AEs and laboratory abnormalities are summarized in Table 2 .
Of the 29 patients enrolled at the US site, the site that participated in the FNA portion of the study, 26 patients were part of the FNA subset with 26, 25, 24, and 17 patients undergoing FNAs at day 1 and weeks 1, 2, and 4, respectively. The week 4 FNA was not offered to the 6 patients in the arm C FNA subset. Procedural pain occurred in 17 of the 26 patients who underwent an FNA and was generally mild in severity. Despite the frequency of procedural pain, 17 out of 20 subjects in arms A and B underwent the optional week 4 FNA procedure.
HCV RNA Decline in Plasma and Liver
In total, data were available from 43 patients on intensive plasma HCV RNA measurement and from 26 patients on hepatic HCV RNA measurements over the first 2 weeks of treatment (Supplementary Figure 3) . Comparing across all 3 study arms using the Kruskal-Wallis test, coadministration of RBV had no significant impact on the median decline in plasma or liver HCV RNA in the first 2 weeks of treatment (Table 3) . Although the rate of HCV RNA decline in the plasma was higher than in liver, this was the case irrespective of RBV dosage. Similarly, RBV dosage did not significantly impact the slope of the second-phase decline in HCV RNA levels within plasma when compared across treatment arms (Figure 1 ). In addition, no differences in HCV RNA kinetics were observed between the 3 RBV dosage schemes when hepatic HCV RNA levels were normalized to total cell count per FNA (Supplementary Figure 4) . The median intrahepatic HCV RNA per cell was near undetectable by week 1 (Figure 2 ).
Pharmacokinetics of Direct-Acting Antivirals
Mean Day 1 C max and T max values and steady-state C trough values for OBV, PTV, RTV, DSV, and DSV M1 are shown in Table 4 . The Day 1 plasma concentration-time profiles for each analyte are presented in Supplementary Figure 5 . For each analyte, concentrations were variable between plasma and liver ( Figure 3 ). At each observed time interval, median DSV and DSV M1 concentrations were higher in plasma than liver. Median OBV concentrations were generally higher in plasma than in liver. Median PTV concentrations in the liver were generally comparable to the plasma up to 9 hours postdose but higher in the liver for the >22 to 26-hour time interval. For RTV, concentrations were variable in plasma and liver at all observed time points.
DISCUSSION
This study evaluated the impact of variable RBV dosing on early HCV RNA kinetics (first 2 weeks of treatment) in the plasma and liver for patients with HCV GT1a infection being treated with OBV/PTV/r plus DSV. In addition, this study was the first to collect human liver FNAs for evaluation of OBV, PTV, RTV, and DSV pharmacokinetics and intrahepatic viral kinetics in patients treated with an all-oral DAA regimen that did not contain interferon. Although RBV has a modest and transient impact on plasma HCV RNA levels as a monotherapy [4, 29] , it has clear effectiveness in reducing rates of virologic failure when combined with other therapies [5-7, 12, 15] . However, the mechanism by which RBV prevents virologic failure, and whether it impacts HCV RNA levels within the liver, are unknown. In this study, the presence of RBV did not appear to affect the rate of HCV RNA decline in plasma or liver during the first 2 weeks of treatment. Consistent with previous work, HCV RNA kinetics in the liver were slower than in plasma [21] ; additionally, global HCV RNA decline was independent of RBV dose. Overall, the rate of [24] was used to model the second-phase decline in plasma HCV RNA levels during treatment. The slope of the modeled data was compared between each treatment arm using Wilcoxon's rank sum test, in order to determine the impact of ribavirin (RBV) dosing on HCV RNA kinetics. There was no statistical impact of RBV dosage on the second-phase decline in HCV RNA during treatment. Abbreviations: WB, weight-based; LD, low dose. virologic failure with OBV/PTV/r plus DSV treatment was low (1 patient), regardless of the RBV dosing scheme utilized. Although no differential impact of RBV on global HCV RNA decline was observed, it is possible the impact of RBV is most significant within the DAA-resistant viral subpopulations.
Specifically, RBV could be most effective against extant viral variants whose total population is below the current level of detection. This notion is supported by the clinical observation that difficult-to-treat subpopulations, such as those with cirrhosis, seem to derive the most benefit from RBV coadministration. One other possibility is that RBV acts by inducing or facilitating error catastrophe during replication of the HCV genome [18] [19] [20] , but is most effective at lower viral loads, below the current threshold of detection. In this study, although no impact of RBV was observed directly on levels of HCV RNA, studies on hepatic gene expression in response to HCV antiviral treatment may offer insight into the therapeutic mechanism of action, particularly that of RBV [30] . The presence of cirrhosis may affect hepatic gene expression or RBV metabolism, potentially resulting in higher intrahepatic RBV concentration. Either these or other mechanisms may be responsible for RBV enhancing DAA efficacy in the presence of cirrhosis. The plasma PK parameters of OBV, PTV, RTV, and DSV from this study were generally comparable to previous reports [31] [32] [33] [34] . OBV, PTV, and DSV all have steady-state volumes of distribution of greater than 100 liters [31] , which suggest that there is wide tissue distribution for each of these DAAs. PTV is primarily metabolized by cytochrome P450 3A4 and is a substrate and inhibitor of organic anion transporting polypeptide (OATP) 1B1/1B3 [34] . OATP1B1 and OATP1B3 are influx transporters expressed on the sinusoidal membrane of hepatocytes that can facilitate liver uptake of PTV. As a result, higher liver than plasma concentrations of PTV may be expected. In this study, liver concentrations of PTV were generally comparable to the plasma concentrations up to 9 hours postdose but were approximately 46-fold higher in the liver for the >22 to 26-hour time interval; however, variability of these measurements was high. Prior studies have also investigated DAA concentrations in liver versus plasma; however, studies have given mixed results. In one study that evaluated drug concentrations in liver samples obtained by FNA, intrahepatic concentrations of telaprevir were lower than in plasma in patients who also received pegylated interferon and RBV [21] . Another study that used samples collected by core needle biopsy revealed higher intrahepatic vaniprevir concentrations than in plasma [35] . These observations suggest that additional studies are required to determine whether liver-to-plasma concentration ratios, particularly of protease inhibitors, are compound specific or if some observed variability can be attributed to sampling methodology or variable hepatocyte numbers between samples.
For patients that underwent FNA, procedural pain was the most common adverse event, although the majority of patients reported that it was mild in severity. Furthermore, no patient discontinued the study due to FNA sampling requirements, and all patients (to whom it was available) elected to undergo the optional FNA procedure. One limitation of this study is the lack of FNA samples within the first few days of treatment, which would have enhanced the comparison of early HCV RNA decline in the plasma versus liver compartments. However, given the roughly equivalent levels of HCV RNA observed in the liver after a week of treatment, regardless of RBV dosing scheme, it is likely that the antiviral impact of RBV is mediated through mechanisms other than direct impact on global HCV RNA decline in the earliest stages of treatment (ie, within the first 2 weeks). This also suggests that RBV does not impinge directly upon HCV RNA levels in patients with cirrhosis, who were not enrolled in this study. Because FNA relies on aspiration to acquire a liver sample, and extensive fibrosis present in the cirrhotic liver can greatly affect the quality of samples obtained in FNA, cirrhotic patients were excluded from the study. However, RBV is most commonly used in more difficult-to-cure patients, such as those with cirrhosis, suggesting a potential mechanism for RBV in boosting DAA efficacy in the cirrhotic setting that may not be applicable in patients without cirrhosis. An additional limitation of this study is the variability in the number of hepatocytes in each FNA sample. In order to correct for this variability, residual nucleic acids from each FNA sample used for HCV RNA quantitation were used to quantify GAPDH expression to determine total cell count per FNA. Similar viral kinetics were observed, regardless of RBV dosage scheme, when total cell count was taken into consideration.
In summary, SVR12 rates for patients with chronic GT1a treated with OBV/PTV/r plus DSV and variable RBV dosing regimens remained high. Although RBV is well known to decrease rates of virologic failure, particularly relapse, when coadministered with HCV antiviral therapy, our data suggest that its impact on SVR is not directly related to accelerating the decrease of intrahepatic HCV RNA levels when combined with an all-oral DAA treatment regimen, at least within the range of detectable viral levels. Furthermore, in response to OBV/PTV/r plus DSV treatment, HCV RNA declined more rapidly in plasma than liver. However, the rate of decline was independent of RBV dosing scheme.
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